Apthera, Inc.'s NeuVax™ Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients
6/2/2008 11:35:25 AM
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--NeuVax (E75) produces a delay in disease recurrence in high-risk, disease-free, HER2-positive prostate cancer patients, according to an analysis of the 5-year follow-up data from a Phase I/II clinical trial. Prostate cancer patients demonstrating various levels of HER2/neu expression were treated with NeuVax to determine the ability of the drug to decrease post-prostatectomy prostate-specific antigen (PSA) and clinical recurrences. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago showed that the median time to recurrence from prostatectomy was 14 months for the treatment group vs. 8.5 months for the control group. Patients with stable PSA throughout the treatment series exhibited a median time to recurrence of 42.7 months (Abstract #3067, Sunday, June 1, 2008, 2:00 p.m. CDT).
comments powered by